SPINK5L2 Inhibitors
SPINK5L2 inhibitors are a class of chemical compounds that interact with the serine protease inhibitor Kazal-type 5-like 2 protein, commonly referred to by its abbreviation SPINK5L2. This protein belongs to a larger family of serine protease inhibitors which are characterized by their ability to bind to and inhibit the function of serine proteases. Serine proteases are a type of enzyme that cleaves peptide bonds in proteins, playing a critical role in various physiological processes by their involvement in digestion, immune response, blood coagulation, and cellular turnover. SPINK5L2 inhibitors are designed to selectively bind to the SPINK5L2 protein, thereby modulating its activity. The inhibition of this particular serine protease inhibitor can affect the balance of proteolytic activity within the body, as SPINK5L2 itself is part of a complex regulatory mechanism that ensures proteases are active only where and when they are needed.
The chemical structure of SPINK5L2 inhibitors can be diverse, yet they share the common trait of being able to specifically interact with SPINK5L2. This specificity is achieved through the inhibitor's ability to mimic the natural substrates of the protease or to fit into the reactive site of the protein, thus preventing the SPINK5L2 from binding to the serine protease it normally regulates. The design of these inhibitors often involves a deep understanding of the structural biology of SPINK5L2, including the shape and charge distribution of its active and binding sites. Researchers may use various techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy to determine the precise arrangement of atoms within the SPINK5L2 protein. With this information, inhibitors can be tailored to interact with the protein with high affinity and selectivity. The development of SPINK5L2 inhibitors also considers the pharmacokinetic properties of the compounds, ensuring that they are stable and can reach the site of the SPINK5L2 protein in adequate concentrations to exert their modulatory effect.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent, non-selective inhibitor of protein kinases, including protein kinase C (PKC), which is involved in various signaling pathways. Inhibition of PKC can lead to decreased phosphorylation and activation of downstream targets, which may indirectly inhibit SPINK5L2 by altering the signaling cascades it is involved in. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which participate in the Akt signaling pathway. By inhibiting PI3K, LY294002 prevents Akt activation, which may indirectly lead to the functional inhibition of SPINK5L2 if the protein is functionally regulated by the PI3K/Akt pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a specific inhibitor of mitogen-activated protein kinase kinase (MEK), which blocks the MAPK/ERK pathway. This pathway is involved in cell proliferation and differentiation, and its inhibition could indirectly affect SPINK5L2 function if SPINK5L2 is regulated by MAPK/ERK signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific mTOR inhibitor and acts by binding to the FKBP12 protein to form a complex that inhibits the mTORC1 complex. mTOR is a central regulator of cell growth and proliferation, and inhibition of mTOR signaling may indirectly affect SPINK5L2 if SPINK5L2 function is linked to mTOR pathway activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase, which is involved in stress and inflammatory responses. By inhibiting p38 MAP kinase activity, SB203580 can influence cellular processes that might be regulating SPINK5L2 activity or expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, effectively inhibiting the MAPK/ERK pathway. This pathway is known to regulate various cellular functions, and its inhibition could lead to an indirect decrease in SPINK5L2 activity if there is a regulatory relationship. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent and irreversible inhibitor of PI3K, leading to the inhibition of the Akt pathway. This compound could indirectly decrease SPINK5L2 functional activity by disrupting pathways that regulate the protein's activity or expression. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in various cellular processes including apoptosis and inflammation. Inhibition of JNK activity could potentially lead to indirect modulation of SPINK5L2 if there is a functional connection between JNK signaling and SPINK5L2 regulation. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, which can disrupt cell cycle progression and mitosis. If SPINK5L2 is involved in cell cycle control, its function could be indirectly inhibited through the disruption of Aurora kinase activity. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. It prevents autophosphorylation of EGFR, leading to the inhibition of downstream signaling pathways that could indirectly affect SPINK5L2 activity if EGFR signaling regulates SPINK5L2 function. | ||||||